EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review

Sarah Hendee iD, Gerald Falchook iD

Journal of Immunotherapy and Precision Oncology · 11.06.2026 · 9 (3) · 79-87

DOI: 10.36401/jipo-25-35 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 11.06.2026. Verfasst von Sarah Hendee und 1 weiteren Autor:innen. Beteiligte Einrichtung: HCA HealthONE, Sky Ridge Medical Center, Lone Tree, CO, USA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SMARCA4 is an ATPase subunit in the switch/sucrose non-fermentable complex (SWI/SNF), a chromatin-remodeling complex. SMARCA4 provides energy for the SWI/SNF complex to regulate gene expression through chromatin structural rearrangement and transcription regulation. In SMARCA4-deficient cancers, its paralog SMARCA2 is sometimes upregulated and can serve as a pharmacological target. Of the 20–25% of cancers identified to have a mutation in a gene encoding a protein for the SWI/SNF complex, 15% of these alterations include SMARCA4 alterations. Therefore, SMARCA4-directed therapies are under investigation in clinical trials and are a promising new strategy for treating patients with a SMARCA4 -mutated cancer. Currently, all published clinical trials of SMARCA4-directed therapies are for orally bioavailable small-molecule inhibitors. Clinical trials without results include small-molecule inhibitors, monoclonal antibodies, and a bifunctional MabPair product. The aim of this literature review was to summarize the current SMARCA4-directed therapies in oncology clinical trials.

Schlagwörter

Stichwörter der Autor:innen

SMARCA4cancerclinical trialsreview article

Autor:innen und Institutionen

  • HCA HealthONE, Sky Ridge Medical Center, Lone Tree, CO, USA.
  • Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

ORCID-Profile: Sarah Hendee, Gerald Falchook

Zitieren

APA

Hendee, S., & Falchook, G. (2026). SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 9(3), 79-87. https://doi.org/10.36401/jipo-25-35

Vancouver

Hendee S, Falchook G. SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2026;9(3):79-87. doi:10.36401/jipo-25-35

BibTeX
@article{Hendee2026,
  author = {Hendee, Sarah and Falchook, Gerald},
  title = {SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {79--87},
  doi = {10.36401/jipo-25-35}
}
Kostenlos starten →